<div id="readability-page-1"><p>Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics, retaining the price target of $1.50.</p><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Jason McCarthy has given his Buy rating due to a combination of factors tied to Plus Therapeutics’ advancing pipeline and strengthened balance sheet. The company ended the year with sufficient cash and subsequently raised additional equity, which McCarthy believes should fund operations into 2027, supporting key value-driving clinical and commercial milestones. </p> <p>He highlights the ongoing ReSPECT-LM and ReSPECT-GBM Phase 2 studies of Reyobiq, both of which are progressing toward potentially pivotal or registration-enabling designs, backed by encouraging prior survival data and FDA feedback. In parallel, he views the growing adoption and payer coverage of the CNSide assay—along with clear 2026 commercialization targets—as an emerging revenue opportunity that complements the therapeutic programs and supports a favorable risk‑reward profile for PSTV shares.</p> <p>In another report released on February 26, Lake Street also maintained a Buy rating on the stock with a $2.00 price target.</p></div>

IBBQ

LABU

PSTV

ARKG

<p>Analyst Jason McCarthy of Maxim Group has maintained a Buy rating on Plus Therapeutics, with a price target of $1.50, citing the company's advancing pipeline and strong balance sheet. The firm raised additional equity, ensuring operations funding through 2027. Key studies for Reyobiq are progressing, and the CNSide assay is expected to generate revenue by 2026. Lake Street also supports the stock with a Buy rating and a $2.00 price target.</p>

Tip Ranks

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Plus Therapeutics

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027